If you or a loved one is taking Tysabri and concerned about progressive multifocal leukoencephalopathy (PML), understanding the early signs and diagnosis process is crucial. Building on decades of medical research, this page provides a focused review of PML detection and safety monitoring for patients on Tysabri therapy.
Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that Tysabri increases the risk of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised patients. In Tysabri-treated patients, three risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The clinical presentation of PML can include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and, in some cases, seizures. Diagnosis is typically confirmed by brain MRI and detection of JC virus DNA in cerebrospinal fluid via PCR. The timeline between Tysabri exposure and documented harm varies. PML can occur after a few months to several years of treatment, with risk increasing with longer duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period is critical for patients and their families when considering legal action.
For patients affected by Tysabri-associated PML, settlement considerations often involve the adequacy of warnings provided by the manufacturer. The boxed warning explicitly states the risk of PML and the need for monitoring, but questions may arise about whether these warnings were sufficiently communicated to patients and healthcare providers before treatment initiation. The TOUCH program is designed to ensure that patients understand these risks, but compliance and effectiveness can vary. Settlement-related considerations for affected patients include the severity of disability, medical expenses, lost income, and pain and suffering. The timeline between exposure and harm is a key factor, as it influences the statute of limitations for filing a claim. In New Jersey, the statute of limitations for product liability claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or should have been discovered. This discovery rule is important because PML symptoms may not appear until months or years after starting Tysabri. Patients and their families should be aware that the clock starts ticking when they knew or reasonably should have known that Tysabri caused the PML. Given the latency period, this could be significantly after the initial exposure. Legal advice should be sought promptly to ensure claims are filed within the applicable time frame.
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4-beta-1 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system, which is beneficial for multiple sclerosis, but it also impairs immune surveillance against JC virus. Without adequate immune cell trafficking, latent JC virus can reactivate and cause PML. This mechanism is well-established and is the basis for the FDA's warnings and the restricted distribution program. In summary, Tysabri carries a significant risk of PML, a severe and often fatal brain infection. Patients with anti-JCV antibodies, longer treatment duration, or prior immunosuppressant use are at higher risk. The FDA requires a boxed warning and a restricted distribution program to mitigate this risk. For affected patients in New Jersey, the statute of limitations for filing a claim is generally two years from discovery of the injury. Given the latency period between exposure and harm, prompt legal consultation is advisable. Settlement considerations should account for the severity of disability, medical costs, and the adequacy of warnings provided.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In New Jersey, the statute of limitations for product liability claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or should have been discovered. This discovery rule is important because PML symptoms may not appear until months or years after starting Tysabri. Patients and their families should be aware that the clock starts ticking when they knew or reasonably should have known that Tysabri caused the PML.
Three risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.